Literature DB >> 8507878

Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization.

R C Friedberg1, S F Donnelly, J C Boyd, L S Gray, P D Mintz.   

Abstract

Numerous independent and interdependent factors are involved in the posttransfusion platelet response. Factors such as ABO match and platelet age are related to circumstances potentially under the control of the blood bank physician and therefore may permit circumvention by an active transfusion service. On the other hand, factors such as fever or sepsis may be unavoidable, being related more to the individual patient or clinical condition. To evaluate which factors could be circumvented, we prospectively followed the 1-hour corrected count increments (CCIs) for 962 single-donor apheresis platelet transfusions to 71 refractory hematologic oncology inpatients, with concomitant recording of implicated factors. Stepwise regression analysis allowed for determination of which concurrent and confounding clinical-, patient-, and blood bank-related factors significantly affected the CCIs. Although many implicated factors proved to be independently associated with an increased or decreased CCI, we found that no single variable consistently explained the CCI variation across the patient population. Each patient appeared sensitive to one or a few particular factors, but because of marked intraindividual variation, it was not possible to identify a priori which factors were important for a given patient. The single exception was a solid-phase red blood cell adherence assay used to cross-match platelets, but only for alloimmunized patients. We also evaluated the utility of requesting HLA-matched platelets from the local suppliers and maintained a clear distinction between platelets simply ordered as HLA matched and actually HLA-identical platelets. Accounting for the confounding clinical-, patient-, and blood bank-related factors, the cross-match assay was a better predictor of an adequate CCI than ordering platelets as HLA matched.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507878

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B.

Authors:  Majed A Refaai; Jessie Carter; Kelly F Henrichs; Donna C Davidson; Stephen J Pollock; Ann E Casey; Sherry L Spinelli; Richard P Phipps; Charles W Francis; Neil Blumberg
Journal:  Transfusion       Date:  2012-05-25       Impact factor: 3.157

2.  Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.

Authors:  Sherrill J Slichter; Douglas Bolgiano; Kuo-Jang Kao; Thomas S Kickler; Janice McFarland; Jeffrey McCullough; Robert Woodson
Journal:  Transfus Med Rev       Date:  2011-02-23

3.  Autologous platelet transfusion in alloimmunized patients with acute leukemia.

Authors:  I Funke; M Wiesneth; K Koerner; M Cardoso; E Seifried; B Kubanek; H Heimpel
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

4.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion.

Authors:  Jeremy Ryan A Peña; Susan L Saidman; Timothy C Girouard; Erin Meister; Walter H Dzik; Robert S Makar
Journal:  Am J Hematol       Date:  2014-06-19       Impact factor: 10.047

6.  Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia.

Authors:  Preeyanat Vongchan; Weerasak Nawarawong; Robert J Linhardt
Journal:  Am J Clin Pathol       Date:  2008-09       Impact factor: 2.493

7.  Therapeutic efficacy of different types of platelet concentrates in thrombocytopenic patients.

Authors:  Ravindra Pratap Singh; Neelam Marwaha; Pankaj Malhotra; Sumitra Dash
Journal:  Indian J Hematol Blood Transfus       Date:  2008-05-01       Impact factor: 0.900

8.  Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India.

Authors:  Vijay Kumawat; Ratti Ram Sharma; Pankaj Malhotra; Neelam Marwaha
Journal:  Asian J Transfus Sci       Date:  2015 Jan-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.